$FOCL

EDAP TMS SA

EDAP, headquartered in Vaulx-en-Velin, France, develops, manufactures, markets and sells non-invasive therapeutic ultrasound and energy-based medical devices. Its business focuses on proprietary High Intensity Focused Ultrasound technology, primarily for urology and the treatment of prostate cancer. Its flagship product is the Focal One i Robotic HIFU System, which enables urologists to target and ablate prostate tissue. EDAP is also pursuing clinical applications for the platform in benign prostatic hyperplasia and endometriosis. EDAP makes money from sales of capital equipment and recurring sales of consumables and maintenance services. It markets Focal One and related products through its own sales channels and selected distributors and agents. The company also markets and supports legacy urology products, including extracorporeal shock wave lithotripsy systems, accessories and services, and distributes third-party laser, micro-ultrasound and urodynamics products. Its customers include hospitals and clinics worldwide.

No enriched coverage for $FOCL in the last 7 days.

No SEC Form 4 filings for $FOCL in the last 30 days.

See all $FOCL insider activity →
Med

FocalTherics Q3 Earnings Call Highlights

FocalTherics reported Q3 earnings, highlighting sales to new hospitals and 32% YoY procedure growth. Revenue rose 24%, gross margin improved to 51.4%, and net loss narrowed to $4.5M. Cash increased to $56.3M post-equity offering. The company expects consistent procedure growth in 2027, with new coverage policies and clinical studies underway.

Edap TMS SA (FOCL) (Q3 2026) Earnings Call Highlights: HIFU Revenue Jumps 26%

Edap TMS SA (FOCL) reported Q3 2026 revenue of $9.8M, up 26% YoY, but missed expectations due to delayed sales. Gross margin improved to 51.4%, while operating loss widened to $7.8M. Full-year guidance was narrowed to $50-$52M. U.S. procedure volumes grew 32% YoY, and reimbursement expanded with NCCN upgrades and commercial payer coverage.

EDAP TMS SA (FOCL): FocalTherics™ Reports Third Quarter 2026 Financial Results

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Third Quarter 2026 Financial Results 45% Revenue Increase and 44% Growth in U.S. Procedure Volume Year-to-date AUSTIN, Texas, November 5, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company” [1] ), a global leader in robotic focal therapy, today a

FOCL sentiment & insider activity

Recent FOCL coverage spans insider activity and earnings.

What's driving FOCL

AlphAI scores every news story that mentions FOCL with an AI model for sentiment and relevance, and aggregates insider trades from EDAP TMS SA's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $FOCL

Score

FocalTherics Q3 Earnings Call Highlights

FocalTherics reported Q3 earnings, highlighting sales to new hospitals and 32% YoY procedure growth. Revenue rose 24%, gross margin improved to 51.4%, and net loss narrowed to $4.5M. Cash increased to $56.3M post-equity offering. The company expects consistent procedure growth in 2027, with new coverage policies and clinical studies underway.

$FOCLMedEarnings

EDAP TMS SA (FOCL): FocalTherics™ Reports Third Quarter 2026 Financial Results

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Third Quarter 2026 Financial Results 45% Revenue Increase and 44% Growth in U.S. Procedure Volume Year-to-date AUSTIN, Texas, November 5, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company” [1] ), a global leader in robotic focal therapy, today a

$FOCLMedAI 8/10

FocalTherics (FOCL) Q2 2026 Earnings Call Transcript

FocalTherics (FOCL) reported Q2 2026 earnings with $13.2M in HIFU revenue, up 39% YoY. They sold 13 Focal One systems, a 44% increase. The company expanded its footprint in the U.S. and internationally, including sales to Cleveland Clinic and Kaiser Permanente. They submitted a 510(k) application for FocalConnect and expect CMS reimbursement increases. The company is also expanding into new indications like BPH and endometriosis, targeting a $10B revenue opportunity.

Related tickers